Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) FCF Margin (2021 - 2025)

Aligos Therapeutics filings provide 5 years of FCF Margin readings, the most recent being 12866.86% for Q4 2025.

  • On a quarterly basis, FCF Margin fell 1230920.0% to 12866.86% in Q4 2025 year-over-year; TTM through Dec 2025 was 3774.15%, a 249354.0% decrease, with the full-year FY2025 number at 3774.15%, down 153452.0% from a year prior.
  • FCF Margin hit 12866.86% in Q4 2025 for Aligos Therapeutics, down from 3285.43% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 121.33% in Q4 2022 to a low of 15995.71% in Q1 2023.
  • Median FCF Margin over the past 5 years was 1632.44% (2021), compared with a mean of 3769.56%.
  • Biggest five-year swings in FCF Margin: crashed -1518090bps in 2023 and later soared 1271819bps in 2024.
  • Aligos Therapeutics' FCF Margin stood at 10304.09% in 2021, then soared by 99bps to 121.33% in 2022, then tumbled by -830bps to 1127.82% in 2023, then skyrocketed by 51bps to 557.67% in 2024, then crashed by -2207bps to 12866.86% in 2025.
  • The last three reported values for FCF Margin were 12866.86% (Q4 2025), 3285.43% (Q3 2025), and 1606.63% (Q2 2025) per Business Quant data.